A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.揭露一種新的人源化抗-IgE抗體。此抗體可結合至游離的IgE、位於B淋巴球上與膜結合的IgE、或與CD23結合的IgE,而非位於肥大細胞上與高親和力IgE.Fc受體結合的IgE。本發明關於藉由投予本發明抗-IgE抗體對IgE介導疾病的治療,IgE介導疾病包括過敏性氣喘、過敏性鼻炎、異位性皮膚炎、食物過敏、慢性自發性(特發性)蕁麻疹、慢性鼻竇炎、系統性肥大細胞增生症、皮膚肥大細胞增生症、過敏性支氣管肺麴菌病、復發性特發性血管性水腫,以及和嗜酸性球有關的腸胃疾病。
